JP Morgan Ups View on Rolls-Royce (RYCEY); Leerink Partners Cuts Price Target on GW Pharma (GWPH)


Investment analysts at JP Morgan upgraded shares of Rolls-Royce Holdings PLC (OTCMKTS:RYCEY) from an Underweight to a Neutral rating

RYCEY stock is trading at $9.46, down $0.19 (or -1.97%), and 17,632 of its shares exchanged hands so far on Thursday

Rolls-Royce Holdings, which designs, develops, manufactures, and services integrated power systems in the UK and internationally, has 1.84B Shares Outstanding and RYCEY stock 52-week range is from $7.33 to $16.12 per share



Brokerage firm Leerink Partners lowered its price target on GW Pharmaceuticals plc (Nasdaq:GWPH) stock from $129.00 to $100.00, while maintaining an Outperform rating

The biopharmaceutical company recently reported first quarter fiscal 2016 revenue of £3.7 million ($5.4 million) and a loss of £17.7 million ($26.2 million) for the period

GWPH shares are exchanging hands at $46.23, down $1.56 (or -3.26%) on Thursday’s trading session

GW Pharmaceuticals, which engages in discovering, developing, and commercializing cannabinoid prescription medicines, has 21.76M Shares Outstanding and GWPH stock one-year range is between $39.93 and $133.98 per share


Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. GalaxyStocks is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at